GlassScriptPhysician profile
Victoria Vardell
NPI 1912460239
$3,591.50
in general payments reported to CMS, 2019-2025
19 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $106 · 2023: $506 · 2024: $1,442 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.15 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $380.94 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $319.31 | 2024-2025 | Calquence |
| Genzyme Corporation | $287.57 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $266.53 | 2024-2025 | |
| Abbvie INC. | $262.46 | 2023-2024 | Venclexta |
| Aveo Pharmaceuticals, INC. | $239.95 | 2024-2025 | |
| Incyte Corporation | $237.52 | 2023-2024 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $230.15 | 2024-2025 | |
| Amgen INC. | $223.44 | 2025 | Imdelltra (Amg757) |
| Adaptive Biotechnologies Corporation | $200.61 | 2024 | Clonoseq |
| Genentech, INC. | $177.45 | 2021 | |
| Karyopharm Therapeutics INC. | $143.53 | 2023 | Xpovio |
| Beone Medicines USA, INC. | $135.88 | 2025 | Brukinsa |
| Genmab U.S., INC. | $126.86 | 2025 | Epkinly |
| Sobi, INC | $105.98 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.97 | 2021 | |
| Glaxosmithkline, LLC. | $75.54 | 2023 | Blenrep |
| Pharmaessentia USA Corporation | $39.25 | 2025 | Besremi |
| Stemline Therapeutics INC. | $38.56 | 2025 | Elzonris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Vardell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.